top of page

ASH 2024: Cambridge, UK based CellCentric has a unique approach to targeting p300/CBP and thus reducing the activation of oncogenes like IRF4 and MYC in multiple myeloma

  • Dec 7, 2024
  • 1 min read

CEO Will West describes how the company focuses on inhibiting the bromodomain of these targets with inobrodib, rather than the active sites, and how this is different than the approaches of other companies. He describes CellCentric's phase 2 data at ASH and the next steps for the program.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page